Published in Expert Opin Emerg Drugs on December 01, 2013
Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites. Clin Transl Med (2015) 0.84
Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis. BMC Gastroenterol (2014) 0.78
First-in-human randomised study of bimekizumab, a humanised monoclonal antibody and selective dual inhibitor of IL-17A and IL-17 F, in mild psoriasis. Br J Clin Pharmacol (2016) 0.76
Vitamin D supplementation of initially vitamin D-deficient mice diminishes lung inflammation with limited effects on pulmonary epithelial integrity. Physiol Rep (2017) 0.75
Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet (2009) 9.45
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med (2012) 6.17
A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet (2008) 5.85
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet (2009) 3.55
A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat Genet (2003) 3.52
Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics (2003) 3.39
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA (2011) 3.29
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med (2010) 2.74
Cutaneous manifestations of gastrointestinal disease: part I. J Am Acad Dermatol (2013) 2.58
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA (2003) 2.50
Cutaneous manifestations of gastrointestinal disease: part II. J Am Acad Dermatol (2013) 2.38
PSORS2 is due to mutations in CARD14. Am J Hum Genet (2012) 2.10
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol (2004) 2.05
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol (2011) 2.03
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol (2008) 1.99
Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet (2012) 1.88
Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome. Hum Mol Genet (2011) 1.74
A subset of methylated CpG sites differentiate psoriatic from normal skin. J Invest Dermatol (2011) 1.73
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol (2004) 1.66
Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. Int J Dermatol (2003) 1.60
Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne. J Am Acad Dermatol (2004) 1.53
Cardiocutaneous syndromes and associations. J Am Acad Dermatol (2002) 1.53
A previous cholecystectomy increases the risk of developing advanced adenomas of the colon. South Med J (2009) 1.49
A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. J Am Acad Dermatol (2009) 1.45
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol (2008) 1.43
Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol (2006) 1.42
Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know. J Am Acad Dermatol (2012) 1.40
PsEma--a hitherto unnamed dermatologic entity with clinical features of both psoriasis and eczema. Skinmed (2005) 1.39
Localization of PSORS1 to a haplotype block harboring HLA-C and distinct from corneodesmosin and HCR. Hum Genet (2005) 1.37
Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol (2004) 1.36
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol (2005) 1.34
Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol (2008) 1.28
The use of cyclosporine in dermatology: part I. J Am Acad Dermatol (2010) 1.26
Novel immunoglobulin superfamily gene cluster, mapping to a region of human chromosome 17q25, linked to psoriasis susceptibility. Hum Genet (2002) 1.24
Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis (2010) 1.22
Comorbidities in psoriasis patients. Semin Cutan Med Surg (2010) 1.21
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med (2015) 1.20
Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. J Drugs Dermatol (2007) 1.17
Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis (2003) 1.16
Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study. JAMA Dermatol (2013) 1.15
Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology (2008) 1.15
Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol (2003) 1.09
The use of cyclosporine in dermatology: part II. J Am Acad Dermatol (2010) 1.07
Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol (2005) 1.07
Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin Biol Ther (2003) 1.04
Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol (2004) 1.03
A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads. J Drugs Dermatol (2005) 1.01
Update on botulinum toxin for facial aesthetics. Dermatol Clin (2002) 1.01
For patients with colorectal cancer, the long-term use of statins is associated with better clinical outcomes. Dig Dis Sci (2009) 0.99
Burden of disease: psoriasis and psoriatic arthritis. Am J Clin Dermatol (2013) 0.98
Long-term use of angiotensin converting enzyme inhibitors is associated with decreased incidence of advanced adenomatous colon polyps. J Clin Gastroenterol (2011) 0.97
Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis. Clin Dermatol (2003) 0.96
Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies. Int J Dermatol (2009) 0.96
Decision points for the initiation of systemic treatment for psoriasis. J Am Acad Dermatol (2005) 0.96
Obesity is associated with an increased prevalence of advanced adenomatous colon polyps in a male veteran population. Dig Dis Sci (2009) 0.95
Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritis. PLoS One (2011) 0.92
Psoriatic arthritis: an update. Arthritis (2012) 0.92
Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. J Drugs Dermatol (2013) 0.91
Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis (2002) 0.91
Quality-of-life instruments: evaluation of the impact of psoriasis on patients. Dermatol Clin (2012) 0.90
Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. Health Qual Life Outcomes (2008) 0.90
Psoriasis and the metabolic syndrome. J Drugs Dermatol (2008) 0.90
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol (2006) 0.89
Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis. Clin Immunol (2004) 0.89
Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat (2007) 0.88
OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis. J Am Acad Dermatol (2013) 0.87
The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis. Mol Diagn Ther (2010) 0.87
Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management. J Am Acad Dermatol (2012) 0.87
Current investigational drugs in psoriasis. Expert Opin Investig Drugs (2012) 0.86
Changing paradigms in dermatology: nuclear hormone receptors. Clin Dermatol (2003) 0.86
Lymphoma and immunosuppression: a report of a case associated with efalizumab therapy. Clin Lymphoma Myeloma Leuk (2010) 0.86
Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol (2009) 0.86
Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United States. Pediatr Dermatol (2013) 0.84
AAD consensus statement on psoriasis therapies. J Am Acad Dermatol (2003) 0.84
Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. J Drugs Dermatol (2008) 0.84
Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol (2007) 0.83
Novel therapies for psoriasis. Am J Clin Dermatol (2002) 0.83
Reduction in low-density lipoprotein cholesterol levels during statin therapy is associated with a reduced incidence of advanced colon polyps. Am J Med Sci (2009) 0.83
Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis. J Drugs Dermatol (2014) 0.83
Tazarotene versus tazarotene plus hydroquinone in the treatment of photodamaged facial skin: a multicenter, double-blind, randomized study. J Cosmet Laser Ther (2006) 0.83
Blue Nevus-Like Metastasis of a Cutaneous Melanoma Identified by Fluorescence In Situ Hybridization. Am J Dermatopathol (2016) 0.83
Topical treatment of psoriasis. Curr Probl Dermatol (2009) 0.81
A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol (2002) 0.81
Ciclopirox gel in the treatment of patients with interdigital tinea pedis. Int J Dermatol (2003) 0.81
Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea. J Drugs Dermatol (2010) 0.80
Infliximab. Dermatol Ther (2004) 0.80
Long-term management of scalp psoriasis: perspectives from the International Psoriasis Council. J Dermatolog Treat (2012) 0.80
Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial. Curr Med Res Opin (2010) 0.79
The use of ustekinumab in autoimmune disease. Expert Opin Biol Ther (2010) 0.79
Atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy. J Drugs Dermatol (2010) 0.79
A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology (2006) 0.79
Pregnancy outcomes in psoriasis: why do we know so little? J Am Acad Dermatol (2009) 0.79
Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. J Drugs Dermatol (2014) 0.78
Efalizumab: continuous therapy for chronic psoriasis. Expert Opin Biol Ther (2005) 0.77
Combining traditional agents and biologics for the treatment of psoriasis. Semin Cutan Med Surg (2005) 0.77
Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis. J Am Acad Dermatol (2007) 0.77
Biological therapies for psoriasis. Expert Opin Biol Ther (2013) 0.77